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RESEARCH ARTICLE
Cortical and Subcortical Glutathione Levels in Adults
with Autism Spectrum Disorder
Alice M.S. Durieux,* Jamie Horder,* M. Andreina Mendez, Alice Egerton, Steven C. R. Williams,
C. Ellie Wilson, Debbie Spain, Clodagh Murphy, Dene Robertson, Gareth J. Barker,
Declan G. Murphy, and Grainne M. McAlonan
Increased oxidative stress has been postulated to contribute to the pathogenesis of autism spectrum disorder (ASD).
However, reports of alterations in oxidation markers including glutathione (GSH), the major endogenous antioxidant,
are indirect, coming from blood plasma level measurements and postmortem studies. Therefore we used in-vivo 3
Tesla proton magnetic resonance spectroscopy ([1H]MRS) to directly measure GSH concentrations in the basal ganglia
(BG) and the dorsomedial prefrontal cortex of 21 normally intelligent adult males with ASD and 29 controls who did
not differ in age or IQ. There was no difference in brain GSH between patients and controls in either brain area; nei-
ther did GSH levels correlate with measures of clinical severity in patients. Thus [1H]MRS measures of cortical
and subcortical GSH are not a biomarker for ASD in intellectually able adult men. Autism Res 2016, 9: 429–435.
VC 2015 The Authors Autism Research published by Wiley Periodicals, Inc. on behalf of International Society for
Autism Research.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmen-
tal condition characterized by repetitive behaviors and
impairments in reciprocal social interactions and com-
munication [American Psychiatric Association, 2013],
affecting about 1% of the population [Baron-Cohen
et al., 2009].
The aetiology of ASD remains unclear, though various
genetic, environmental and immunological factors are
thought to influence the development of the disorder
[Deth, Muratore, Benzecry, Power-Charnitsky, & Waly,
2008]. Among these, oxidative stress—particularly that
arising from toxic environmental exposures—has been
proposed to play a central role in its pathogenesis
[Chauhan & Chauhan, 2006; Deth et al., 2008; Deth,
2013; Theoharides, Kempuraj, & Redwood, 2009]. This
“Redox Hypothesis” is supported by reports of increased
markers of oxidative stress and lipid peroxidation in
individuals with ASD, including elevated red blood cell
nitric oxide, decreased plasma levels of antioxidant
proteins, and an imbalance between the reduced and
oxidised forms of glutathione (GSH) [Chauhan, Chau-
han, Brown, & Cohen, 2004; Kern & Jones, 2006].
GSH is the major endogenous cellular antioxidant. It
protects against lipid peroxidation and oxidative stress, by
maintaining the balance between production and
removal of reactive oxygen species (ROS) [Shimizu et al.,
1998]. Lower levels of GSH and higher levels of its oxi-
dized metabolite, GSSG, have been reported in the plasma
of individuals with ASD and this has been suggested to
indicate greater oxidative stress [Frustaci et al., 2012; Geier
et al., 2009; James et al., 2004; Main, Angley, O’Doherty,
Thomas, & Fenech, 2012]. However, it is unclear whether
this decrease in peripheral GSH also occurs in the brain.
Decreased GSH, increased GSSG, and a decreased
GSH:GSSG ratio have been reported in the cerebellum and
temporal cortex of subjects with ASD post-mortem
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[Chauhan, Audhya, & Chauhan, 2012]. However, post-
mortem studies are limited by the quality of protein pres-
ervation [Ferrer, Martinez, Boluda, Parchi, & Barrachina,
2008], therefore GSH concentrations in the ASD brain also
need to be researched in vivo.
Brain GSH can be measured in vivo using the tech-
nique of proton magnetic resonance spectroscopy
([1H]MRS). This approach has been applied to individu-
als with various neuropsychiatric disorders using a 3T
scanner. For instance, temporal cortex GSH levels have
been reported to be higher in people with psychosis,
whereas no difference in brain GSH has been found in
those with bipolar disorder [Godlewska, Yip, Near,
Goodwin, & Cowen, 2014; Lagopoulos et al., 2013;
Wood et al., 2009]. However to date, no-one has exam-
ined [1H]MRS measures of GSH in ASD.
Therefore, in this study, we compared brain GSH in
unmedicated adult men with ASD and healthy controls of
similar age and IQ using [1H]MRS. [1H]MRS spectra were
acquired in the basal ganglia (BG) and in the dorsomedial
prefrontal cortex (DMPFC). These regions were chosen
because they have been consistently reported to have
both structural abnormalities and functional deficits (rele-
vant to the core symptoms) in ASD (e.g. see [Haznedar
et al., 2006; Hollander et al., 2005; Horder et al., 2013;
Schmitz, Daly, & Murphy, 2007]. For instance, anomalies
in the BG are thought to be responsible for repetitive
behaviors [Hollander et al., 2005; Naaijen, Lythgoe, Amiri,
Buitelaar, & Glennon, 2015], while frontal network defi-
cits have been implicated in social symptoms [Bernhardt
et al., 2014; Watanabe et al., 2012; Wicker et al., 2008].
We tested the hypotheses that men with ASD have lower
GSH than controls and that this would correlate with the
severity of ASD symptoms [assessed using the Autism
Observation Schedule (ADOS) [Lord, Rutter, DiLavore, &
Risi, 1999] and the Autism Diagnostic Interview—Revised
(ADI) [Lord, Rutter, & Le Couteur, 1994] for current and
past symptoms respectively]. As co-morbid symptoms of
anxiety, depression and ADHD are common in ASD [Mat-
son & Cervantes, 2014; Mazzone, Ruta, & Reale, 2012], we
also explored potential correlations between GSH levels
and symptoms rated using the State-Trait Anxiety Inven-
tory (STAI) [Ferreira & Murray, 1983], the Beck depression
inventory (BDI) [Beck, Ward, Mendelson, Mock, &
Erbaugh, 1961] and the Barkley self-reported childhood
and adulthood scales (BSSR-Child and BSSR-Adult) [Bark-
ley & Murphy, 1998], respectively.
Materials and methods
Participants
Twenty one male participants with ASD and 29 healthy
men who did not differ in IQ or age were included in
this study. Participants were aged 18–50. All participants
were right handed and had not been taking
psychoactive medication for at least six weeks prior to
the study. Full scale IQ was assessed by a trained
researcher using the Wechsler Abbreviated Scale of Intel-
ligence [Rudie et al. 2013]. Only participants with
IQ>80 were included in this study. Participants with
ASD were recruited from the Behavioural Genetics Clinic
at the Maudsley Hospital, a specialist adult autism diag-
nostic clinic. All had been diagnosed with autism by
experienced psychiatrists according to the ICD-10 crite-
ria (2009). The diagnosis was confirmed using the ADI
and/or ADOS. We excluded individuals with a comorbid
psychotic illness, epilepsy, a history of head injury, or a
genetic disorder (e.g., Fragile X syndrome) known to be
associated with ASD. Symptoms of anxiety, depression
and attention deficit and hyperactivity disorder (ADHD)
were measured using the STAI [Ferreira & Murray, 1983],
the BDI and the BSSR-Child and BSSR-Adult scales
respectively. All participants provided written informed
consent to participate. This study was approved by Essex
2 National Research Ethics Committee.
[1H]MRS Data Acquisition and Processing
[1H] MRS data were acquired on a 3T GE HDx MRI
scanner (GE Medical Systems, Milwaukee, WI, USA). A
structural MRI scan for subsequent voxel positioning
was acquired using a 3D fast inversion-recovery pre-
pared gradient echo acquisition with TI5450 ms,
TR57 ms, TE52.8 ms, matrix5256 3 256 over a 240
3 240 mm field of view, giving a 0.9375 3 0.9375 mm
in plane voxel size, 124 3 1.1 mm slices (partitions).
[1H]MRS spectra were acquired using point-resolved
spectroscopy (PRESS) [Bottomley, 1987]. One voxel (20
3 20 3 15 mm3) was placed in the left basal ganglia
(BG), including the head of the caudate, the anterior
putamen, and the internal capsule. Another voxel (16
3 24 3 20 mm3) was placed in the left DMPFC (see Fig.
1). PRESS parameters were: TR53000 ms, TE530 ms.
One hundred twenty-eight averages were collected in
the BG voxel and 96 in the DMPFC voxel. [1H]MRS
spectra were processed using LCModel software version
6.3-0I [Provencher, 1993].
Data were analysed with a basis set optimized for the
detection of glutathione, which also included the fol-
lowing metabolites: alanine, aspartate, creatine,
gamma-aminobutyric acid (GABA), glutamine, gluta-
mate, GSH, glucose, glycerophosphocholine, phospho-
choline, phosphocreatine, myo-inositol (mI), lactate, N-
acetyl-aspartate (NAA), N-acetyl-aspartylglutamate
(NAAG), scyllo-inositol, and taurine. However, only
GSH was considered here.
Spectra were first reviewed visually to verify that spec-
tra were not qualitatively abnormal. Poorly fitted
metabolite estimates, defined as Cramer-Rao lower
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bounds (CRLB) >20%, were excluded from further
analysis.
Calculation of GSH Concentrations
To control for inter-individual differences in voxel tis-
sue composition, the proportion of grey matter (GM),
white matter (WM), and cerebrospinal fluid (CSF) in
each voxel was calculated. This method provides a use-
ful alternative to reporting metabolite concentrations as
ratios to Creatine content [Brooks et al., 2001; Gussew,
Erdtel, Hiepe, Rzanny, & Reichenbach, 2012]. The struc-
tural MRI was segmented into GM, WM and CSF using
Statistical Parametric Mapping software (SPM2; http://
spm.ion.ucl.ac.uk) and percent tissue class of each voxel
was calculated using in-house software as previously
described [Horder et al., 2013]. Raw metabolite values
were corrected for CSF as follows:
GSHcorrected5 GSHRaw=ð12ProportionCSFÞ
Where ProportionCSF ranged between 0 and 1, and
was calculated individually for each voxel. Raw metabo-
lite values corrected for CSF are referred to as corrected
GSH concentrations in the rest of this article.
Statistical Analysis
All data were analysed in IBM SPSS 21. Group differen-
ces in demographic variables and symptom severity
were determined using independent sample t-tests. To
investigate potential differences in GSH between
groups, we used a general linear model with corrected
GSH concentrations as the dependent variable, group as
a between subjects factor, and age as covariate, to
account for any GSH variation with age [Currais &
Maher, 2013; Maurya & Rizvi, 2010].
The relationship between GSH and the severity of
current ASD symptoms measured using the three sub-
scales of the ADOS, of past ASD symptoms (three sub-
scales of the ADI) and of anxiety, depression and ADHD
symptoms (STAI, BDI, BSSR child and adult scales) was
assessed using Pearson correlation coefficient or Spear-
man’s rank correlation coefficient, depending on the
data distribution. To account for multiple comparisons
in these analyses, we used a “family wise” error correc-
tion. The P-value threshold of 0.05 was divided by 3 for
analyses of correlations with three subscales of the
ADOS; it was also divided by 3 for analyses of correla-
tions with three subscales of the ADI; and it was




There was no significant difference in age or IQ
between the ASD and control groups. As expected, the
participants with ASD scored higher than controls on
the questionnaire measures of depression, anxiety, and
attention-deficit disorder symptoms (all F>4.7, all
P<0.04). Participant characteristics are summarised in
Table I. After excluding spectra where the uncertainty
(% CRLB) of the GSH estimates were greater than 20%
the sample size was 13 patients and 19 controls for the
DMPFC voxel, and 16 patients and 18 controls for the
BG voxel.
Glutathione
There was no significant effect of group on corrected
GSH concentrations in either voxel (F<0.9, P>0.1);
Figure 1. Example of the location of the proton magnetic resonance spectroscopy voxel in the dorsomedial prefrontal cortex (a),
and in the basal ganglia (b).
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neither was there a main effect of age, or an interaction
between group and age. The results were unchanged
when GSH was examined as a ratio to total Creatine (all
P>0.3). Mean corrected GSH concentrations are shown
in Figure 2.
Correlations with Symptom Measures
In the ASD group there were no significant correlations
between GSH concentrations in either voxel and scores
on the ADOS, the ADI, the BDI, the STAI and the BSSR
scales.
Tissue Composition and Data Quality
There was no significant group difference in percentage
of grey matter, white matter or CSF in either voxel. Fig-
ure 3 shows an example of [1H]MRS spectrum after
LCModel 6.3-0I fitting.
Discussion
This is the first study to quantify glutathione (GSH)
brain concentrations in vivo in unmedicated adult men
with ASD compared to healthy controls. We observed
no group differences in GSH concentrations in either
the basal ganglia or the dorsomedial prefrontal cortex
and no relationship between GSH levels and clinical
symptoms.
Our finding contrasts with prior investigations that
have reported decreased GSH in blood plasma in ASD
[James et al., 2004], however, it is consistent with post-
mortem evidence reporting no difference in GSH in the
frontal cortex of individuals with ASD [Chauhan et al.,
2012]. Thus, our findings do not support the hypothesis
that neuronal damage, secondary to oxidative stress
caused by deficient GSH contributes to ASD pathogene-
sis [Deth et al., 2008; Main et al., 2012].
We emphasize that our study included only right
handed males with normal intelligence. Therefore, it
remains possible that GSH abnormalities exist in other
subgroups of individuals with ASD, for example,
women, or those with intellectual disability. Age may
be especially important to consider in this context
because GSH levels have been reported to vary in other
age groups [Currais & Maher, 2013; Maurya & Rizvi,
2010]. For example, prior investigations have found
that GSH is significantly lower in children with ASD
[Chauhan et al., 2012; Frustaci et al., 2012; James et al.,
2004]. Future longitudinal studies are needed to address
this.
Alternatively, it is possible that a difference in GSH
concentrations does exist in the population that we
studied, but that we were unable to detect it (Type II
Figure 2. Mean corrected glutathione concentrations in the dorsomedial prefrontal cortex and the basal ganglia did not differ sig-
nificantly between groups. Error bars represent the standard error of the mean. (GSH, Glutathione; BG, Basal Ganglia; DMPFC, Dorso-
medial Prefrontal Cortex).
Table I. Participant Characteristics
Characteristic ASD Patients Healthy controls
Age 31.82 (8.63) 26.94 (7.39)
ADOS Social behavior 16.47 (5.97) Not applicable
Communication 12.49 (7.26) Not applicable
ADI Social behavior 16.47 (5.97) Not applicable
Communication 12.49 (7.26) Not applicable
Repetitive behavior 4.67 (2.94) Not applicable
BDI 8.97 (10.23) 3.00 (4.43)
STAI 52.19 (12.90) 35.29 (8.88)
BSSR Childhood scale 6.35 (5.04) 1.95 (2.01)
BSSR Adulthood scale 3.60 (3.62) 1.50 (1.58)
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error). Our sample size was modest, reflecting our deci-
sion to limit our sample to those individuals who were
not taking any medications that might affect brain
chemistry. However, our sample size was similar to that
of Wood et al. [2009] who found a robust 22% differ-
ence in GSH concentrations at threshold of P<0.05
using similar approaches in individuals with schizo-
phrenia, and larger than that of Godlewska et al. [2014]
who found no difference in GSH concentrations
between bipolar participants and healthy controls. In
addition, a post hoc power calculation based on the
present data confirmed that if any group differences do
exist these are likely to be extremely small and there-
fore arguably trivial; as a total sample size of at least
n51200 would be necessary for detection (80% power,
at P<0.05).
Our study has a number of other limitations. We did
not exclude participants with co-morbid anxiety, depres-
sion and ADHD symptoms, but we measured these symp-
toms using validated clinical scales. We found that ASD
participants had higher levels of symptoms than con-
trols. However this was not unexpected. These are very
common comorbidities in ASD and a sample without
any comorbid disorders would be quite unrepresentative
for the spectrum [Mazzone et al., 2012].
From a methodological perspective, GSH is often
quantified using a J-edited MEGAPRESS sequence with a
longer echo time (TE), but we employed a short TE
PRESS sequence to quantify GSH. However, others have
shown that GSH can be measured using PRESS at simi-
lar echo times [Lagopoulos et al., 2013; Wood et al.,
2009]. While the test-retest reliability of PRESS GSH
estimates have never been specifically investigated,
PRESS is known to provide reliable quantification for
other common metabolites [Fayed, Modrego, &
Medrano, 2009].
A further consideration is that we investigated only
the basal ganglia and the dorsomedial prefrontal cortex
and differences in GSH might yet be found in other
brain areas. For example, lower levels of GSH in ASD
have been reported in the temporal lobe and cerebel-
lum postmortem [Chauhan et al., 2012]. Indeed, con-
centration differences in other brain metabolites are
known to be regionally specific in ASD [Horder et al.,
2013]. Finally, we did not measure the oxidised coun-
terpart of GSH, GSSG. Hence we cannot exclude the
possibility that GSSG levels are altered in our ASD sam-
ple, resulting in GSH redox imbalance.
In summary, the data presented here suggest that oxi-
dative stress resulting from low levels of GSH is not a
feature of adult men with normal IQ and ASD. How-
ever, we cannot exclude the possibility that further
exploration of GSH in other subgroups of ASD (for
example, those with low IQ), and at different ages, may
help identify individuals who may benefit from anti-
oxidant treatments.
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